Corbus Pharmaceuticals welcomes Dr. Anne Altmeyer to its Board of Directors

– USA, MA –  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), an immunology company, today announced the appointment of Dr. Anne Altmeyer (Ph.D., MPH) to its board of directors.

About Dr. Anne Altmeyer

Dr. Altmeyer is currently the President and CEO of TigaTx, Inc. She previously served as CBO of Sigilon Therapeutics and Adicet Bio. Dr. Altmeyer also held roles of increasing responsibility in corporate development and program management over 15 years across large pharmaceutical organizations. Specifically, Dr. Altmeyer served as VP in Global Business Development at Baxalta and Oncology Business Development and Companion Diagnostics at Novartis. Dr. Altmeyer began her industry career in program management roles at Merck & Company.

She received her Ph.D. from the University Louis Pasteur, Strasbourg, France, and did her postdoctoral fellowships at New York University and Cornell University Medical College in New York City. She also has an MBA from Rutgers University and a master’s in Public Health from the Robert Wood Johnson Medical School, in New Jersey.

Dr. Altmeyer said, “I am honored to join the Corbus Board and look forward to working with the Corbus Team and the Board toward advancing the mission of developing new immune-oncology therapeutics for cancer patients.”

About Corbus

Corbus is an immunology company committed to helping people defeat serious illnesses by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.